Julie Gralow, Chief Medical Officer of the American Society of Clinical Oncology, shared a post on LinkedIn:
“What has 50 years of steady federal investment in cancer research built?
Extraordinary advances that have transformed the meaning of a cancer diagnosis in the U.S. This progress has meant more birthdays, more treasured family moments, and more dreams fulfilled.
Consider how far we’ve come:
- The U.S. cancer death rate has dropped by one-third since the 1990s.
- Once-deadly diagnoses, such as childhood acute lymphoblastic leukemia and testicular cancer, now boast remarkable 5-year survival rates exceeding 90%.
- Today, there are more than 18 million cancer survivors in the U.S., an increase of 15 million since 1971.
- Federal funding has laid the groundwork for innovations like immunotherapy and targeted therapies, discoveries that have redefined treatment and changed countless lives.
Sustaining federal cancer research funding isn’t optional. It’s the indispensable path to continuously unlocking groundbreaking discoveries in cancer prevention, detection, and treatment. We must protect this progress by providing the steady, long-term investments complex breakthroughs require.
Thankfully, Congress is listening. Earlier today members of the House and Senate released a bipartisan funding package that would increase overall NIH and NCI funding for FY 2026.
Take action with us and urge passage of this bill as soon as possible.”
More posts featuring Julie Gralow.